Letrozole is one kind of aromatase inhibitors which may have effect on decrease estrogen in luteal phase and inhibit the luteal function of ovary. In 2009, Letrozole was reported as one candidate for the treatment or prevention of ovarian hyperstimulation syndrome.
Letrozole was proved to be effective in decreasing the estradiol level of luteal phase after ovum picked up. In this randomized controlled study, investigators try to observe the effectiveness of letrozole on decreasing the incidence of early ovarian hyperstimulation syndrome and vascular epithelium growth factor level of women with high ovarian hyperstimulation syndrome risks.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Enrollment
100
incidence of early OHSS
Time frame: up to 1 months
vascular endothelial growth factor level
vascular endothelial growth factor in pg/ml
Time frame: up to 1 months
incidence of hydrothorax
Time frame: up to 1 months
incidence of liver dysfunction
Time frame: up to 1 months
incidence of renal dysfunction
Time frame: up to 1 months
incidence of electrolytic imbalance
Time frame: up to 1 months
incidence of hemoconcentration
Time frame: up to 1 months
incidence of elevated WBC
Time frame: up to 1 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.